Bevacizumab in the therapy for refractory metastatic colorectal cancer.
Colorectal cancer is the second most common cause of cancer related deaths in the United States. Recent developments have led to prolonged survival with the use of sequential lines of chemotherapy agents. The addition of bevacizumab to active chemotherapy has further improved survival when used in the first and second lines of therapy for metastatic colorectal cancer. Evidence supporting the continued use of bevacizumab throughout lines of therapy is accumulating. Clinical trials are underway in which bevacizumab is continued beyond the first line of a chemotherapy and bevacizumab combination regimen. The mechanism by which colorectal cancer may become resistant to bevacizumab is poorly understood. Molecular and biochemical correlates which may identify bevacizumab resistance are an important component in the design of these clinical trials.
Mulcahy
Mary F
MF
Northwestern University, Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Chicago IL, USA.
Nature. 1993 Apr 29;362(6423):841-4
7683111
J Clin Oncol. 2006 Jan 20;24(3):394-400
16421419
J Clin Pathol. 2004 May;57(5):504-12
15113858
J Clin Oncol. 2004 Jan 15;22(2):229-37
14657227
Expert Opin Investig Drugs. 2002 Dec;11(12):1715-36
12457433
J Clin Oncol. 2005 Aug 1;23(22):4866-75
15939922
N Engl J Med. 2003 Jul 31;349(5):427-34
12890841
J Clin Oncol. 2003 Jun 1;21(11):2059-69
12775730
J Clin Oncol. 2005 Jun 1;23(16):3697-705
15738537
J Clin Oncol. 2006 Jul 20;24(21):3354-60
16849749
Sci Am. 1994 Jul;271(1):58-65
8066425
J Clin Oncol. 2000 Aug;18(16):2938-47
10944126
Clin Colorectal Cancer. 2006 May;6(1):66-9
16796794
Lancet. 2000 Mar 25;355(9209):1041-7
10744089
J Clin Oncol. 2004 Jan 1;22(1):23-30
14665611
N Engl J Med. 2004 Jun 3;350(23):2335-42
15175435
J Clin Oncol. 2004 Apr 1;22(7):1209-14
15051767
J Clin Oncol. 2007 Apr 20;25(12):1539-44
17442997
Eur J Cancer. 2001 May;37(8):1000-5
11334725
Lancet. 1998 Oct 31;352(9138):1413-8
9807987
Science. 2005 Jan 7;307(5706):58-62
15637262
Lancet. 1998 Oct 31;352(9138):1407-12
9807986
J Clin Oncol. 2007 Oct 10;25(29):4557-61
17876013
J Clin Oncol. 2006 Jan 10;24(2):217-27
16365183
Endocr Rev. 1997 Feb;18(1):4-25
9034784
J Clin Oncol. 2005 Jun 1;23(16):3706-12
15867200
Ann Oncol. 2000 Nov;11(11):1477-83
11142489
Nat Med. 2004 Feb;10(2):145-7
14745444
N Engl J Med. 2000 Sep 28;343(13):905-14
11006366
Oncologist. 2000;5 Suppl 1:11-5
10804085
N Engl J Med. 2004 Jul 22;351(4):337-45
15269313
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
17237035
J Natl Cancer Inst. 2005 Jul 6;97(13):981-9
15998951